Anuh Pharma LimitedNSE: ANUHPHR

ANUHPHR: Revenue and profit declined in Q3 FY25, with EBITDA margin at 9.86%

· Issued by Anuh Pharma Limited

Q3 FY25 saw a decline in revenue and net profit year-over-year, with EBITDA margin dropping to 9.86%. The company completed a strategic investment in Houban Energy 5 Private Limited during the quarter.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Anuh Pharma

All Anuh Pharma news releases